BCTX BriaCell Therapeutics Corp.

7.39
-0.24  -3%
Previous Close 7.63
Open 7.6
52 Week Low 2.8149
52 Week High 9.5
Market Cap $112,811,679
Shares 15,366,396
Float 15,269,583
Enterprise Value $98,468,400
Volume 683,677
Av. Daily Volume 2,149,651
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Bria-IMT with retifanlimab and epacadostat
Breast cancer
Phase 1/2
Phase 1/2
Phase 1/2 trial open for enrollment - July 14, 2021.
Bria-IMT + retifanlimab and KEYTRUDA (pembrolizumab)
Breast cancer
Phase 1/2
Phase 1/2
12.0 months average overall survival benefit shown in combo arm.

Latest News

  1. BERKELEY, Calif. and VANCOUVER, British Columbia, Oct. 05, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, acknowledges that October is Breast Cancer Awareness Month, an annual campaign to increase awareness of the disease. Significant progress has been made in breast cancer support, prevention, detection, diagnosis, treatment, and care – yet the estimated 43,600 breast cancer deaths per year in the U.S. still indicates a considerable need for more effective treatments.

    Note from BriaCell's Chairman of the Board

    October is Breast Cancer Awareness Month; yet, sadly…

    BERKELEY, Calif. and VANCOUVER, British Columbia, Oct. 05, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, acknowledges that October is Breast Cancer Awareness Month, an annual campaign to increase awareness of the disease. Significant progress has been made in breast cancer support, prevention, detection, diagnosis, treatment, and care – yet the estimated 43,600 breast cancer deaths per year in the U.S. still indicates a considerable need for more effective treatments.

    Note from BriaCell's Chairman of the Board

    October is Breast Cancer Awareness Month; yet, sadly, for millions touched by the pain and death of breast cancer, their Awareness is eternal. BriaCell's clinical aim to attack and destroy breast cancer tumors is also eternal, as we tirelessly advance our targeted immunotherapy clinical program and work with world-class cancer centers to recruit and treat patients.

    Breast Cancer Awareness Month brings the awareness that BriaCell is not treating ‘subjects' or ‘n='. We are treating women – mothers, daughters, sisters, wives, and friends. Breast cancer kills 120 women each day in the U.S. alone. BriaCell's work has already demonstrated clinical benefit in trials thus far to patients who had failed multiple prior treatments.  There exists a unique opportunity to advance BriaCell's achievements on behalf of breast cancer patients, survivors and deceased, and their families.

    BriaCell has emerged in 2021, with $57 million in cash as of July 31, 2021 and clinical advancements that support our mission. In June, we reported a 12.0 months overall survival benefit in advanced breast cancer patients, including 21.4 months of survival benefit for a woman with an eye-bulging tumor that was 100% resolved after our treatment. This particular woman was treated in our Phase I/IIa clinical trial in combination with immune checkpoint inhibitors, including pembrolizumab (KEYTRUDA®; manufactured by Merck & Co.) and, more recently, Incyte's retifanlimab (INCMGA00012) under a corporate collaboration with Incyte Corporation.

    Most recently, we announced a securities buyback program to purchase up to 10% of common shares in the capital of the Company listed on the TSX Venture Exchange and the Nasdaq, and up to 10% of listed warrants on the Nasdaq, with the aim to further enhance value for our shareholders.

    Finally, I encourage shareholders, prospective shareholders, and other stakeholders to contact me directly if you wish to further understand the strategy we have deployed to achieve our primary goals of accelerating BriaCell's remarkable clinical work while maximizing shareholder value. 

    Thank you for your continued support in our fight.

    Sincere regards,

    Jamieson Bondarenko

    Director and Chairman of the Board

    BriaCell Therapeutics Corp.

    investors@briacell.com

    Breast Cancer: Facts & Statistics (U.S.)

    Per the American Cancer Society 2021 report:

    • After skin cancer, breast cancer is the most frequently diagnosed cancer in women, with 281,550 women expected to be diagnosed with invasive breast cancer in 2021;
    • The average risk of a woman developing breast cancer sometime in her life is about 13%. This means there is a 1 in 8 chance she will develop breast cancer;
    • An estimated 43,600 women are expected to die from breast cancer in 2021, which would make breast cancer the second leading cause of cancer death in women after lung cancer.

    About BriaCell Therapeutics Corp.

    BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.

    Safe Harbor

    This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    Contact Information

    Company Contact:

    William V. Williams, MD

    President & CEO

    1-888-485-6340

    info@briacell.com

    Media Relations:

    Jules Abraham

    Director of Public Relations

    CORE IR

    917-885-7378

    julesa@coreir.com 

    Investor Relations Contact:

    CORE IR

    investors@briacell.com



    Primary Logo

    View Full Article Hide Full Article
  2. AUSTIN, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. ("SCV") announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT), to discuss three key achievements that support the Company's continued growth.

    BriaCell is a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer. Speaking with SCV's Stuart Smith, Dr. Williams first detailed the importance of BriaCell's recent collaboration with ImaginAb to evaluate the safety and efficacy of the Company's immunotherapy treatments in patients with advanced breast cancer.

    Dr. Williams also discussed the expansion of BriaCell's board of directors to include…

    AUSTIN, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. ("SCV") announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT), to discuss three key achievements that support the Company's continued growth.

    BriaCell is a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer. Speaking with SCV's Stuart Smith, Dr. Williams first detailed the importance of BriaCell's recent collaboration with ImaginAb to evaluate the safety and efficacy of the Company's immunotherapy treatments in patients with advanced breast cancer.

    Dr. Williams also discussed the expansion of BriaCell's board of directors to include Marc Lustig, an expert in corporate finance and the pharmaceutical industry, as well as the Company's decision to use its excess capital to repurchase its securities.

    "We have over $55 million in the bank and our programs are moving forward," he said. "We're in the clinic with a clinical asset that has positive proof of concept data, but our valuation is that of a pre-clinical type of company … We want to show people that we are very serious about moving our stock forward and also getting our capital markets aligned with where we ought to be, in terms of the valuation of the Company."

    The full interview can be heard at: https://www.smallcapvoice.com/interview-briacell-therapeutics-corp-bctx/.

    About BriaCell Therapeutics Corp.

    BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://BriaCell.com/

    About SmallCapVoice.com

    SmallCapVoice.com, Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies, small cap and micro-cap stocks build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, podcasts, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTCMarkets. To learn more about SmallCapVoice.com and its services, please visit https://www.smallcapvoice.com/small-cap-stock-otc-investor-relations-financial-public-relations/.

    Socialize with SmallCapVoice and their clients at

    Facebook: https://www.facebook.com/SmallCapVoice/  

    Twitter: https://twitter.com/smallcapvoice   

    Instagram: https://www.instagram.com/smallcapvoice/

    Safe Harbor

    This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    Contact Information:

    Company Contact:

    William V. Williams, MD

    President & CEO

    1-888-485-6340

    Info@BriaCell.com

    Media Relations:

    Jules Abraham

    Director of Public Relations

    CORE IR

    917-885-7378

    Info@BriaCell.com

    Investor Relations Contact:

    CORE IR

    Investors@BriaCell.com

    SmallCapVoice.com

    Stuart T. Smith

    512-267-2430

    Info@SmallCapVoice.com

    Source: SmallCapVoice.com

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe8c4141-d54e-4867-ac51-848adae120da



    Primary Logo

    View Full Article Hide Full Article
  3. BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announces that the TSX Venture Exchange (the "TSXV") has accepted the Company's Notice of Intention to implement a normal course issuer bid (the "Buyback").

    Pursuant to the Buyback, the Company may, during the 12-month period commencing on September 28, 2021 and ending September 27, 2022 purchase, through the facilities of the TSXV or The Nasdaq Capital Market ("Nasdaq") or alternative exchanges, (i) up to 1,341,515 common shares (the "Common Shares…

    BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announces that the TSX Venture Exchange (the "TSXV") has accepted the Company's Notice of Intention to implement a normal course issuer bid (the "Buyback").

    Pursuant to the Buyback, the Company may, during the 12-month period commencing on September 28, 2021 and ending September 27, 2022 purchase, through the facilities of the TSXV or The Nasdaq Capital Market ("Nasdaq") or alternative exchanges, (i) up to 1,341,515 common shares (the "Common Shares") and (ii) up to 411,962 publicly traded BCTXW warrants (the "Listed Warrants") in total, representing 10% of the 13,415,154 Common Shares and 10% of the 4,119,622 Listed Warrants, respectively, that comprise the "public float" as of September 21, 2021. Independent Trading Group (ITG) Inc. will act as the Company's advisor and dealer manager in respect of the Buyback. The Buyback will in no way interfere with BriaCell's ambitious growth plans to expand into previously-announced areas of cancer immunotherapy and/or advance its current breast cancer clinical trials.

    A copy of the Form 5G - Notice of Intention to make a Normal Course Issuer Bid filed by the Company with the TSXV can be obtained from the Company upon request without charge.

    BriaCell's proposed repurchases may be conducted through open market transactions at prevailing market prices, in privately negotiated transactions, in block trades, and/or through other legally permissible means, subject to the market conditions and in compliance with applicable rules and regulations. The timing and dollar amount of repurchase transactions will be subject to the Securities and Exchange Commission (the "SEC") Rule 10b-18 and/or Rule 10b5-1 requirements. Purchases of Common Shares or Listed Warrants through the Nasdaq will not, during the 12-month period, exceed 5% of the outstanding Common Shares or Listed Warrants in the aggregate and as of the commencement of the Buyback. BriaCell's Board of Directors will be reviewing the program periodically and may revise the terms and/or size or suspend or discontinue the program.

    About BriaCell Therapeutics Corp.

    BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.

    Safe Harbor

    This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    Contact Information

    Company Contact:

    William V. Williams, MD

    President & CEO

    1-888-485-6340

    info@briacell.com

    Media Relations:

    Jules Abraham

    Director of Public Relations

    CORE IR

    917-885-7378

    julesa@coreir.com

    Investor Relations Contact:

    CORE IR

    investors@briacell.com



    Primary Logo

    View Full Article Hide Full Article
  4. BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 16, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces today that the Company will be presenting at the Benzinga Healthcare Small Cap Conference, which is being held virtually on September 29-30, 2021.

    Dr. Bill Williams, BriaCell's President and CEO, will deliver his corporate presentation at 1:15pm ET on September 29.  Management will be available for one-on-one meetings to be held throughout the conference. Investors can register to receive a free spectator pass for the event: https://www.benzinga.com/events/small-cap/healthcare/

    BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 16, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces today that the Company will be presenting at the Benzinga Healthcare Small Cap Conference, which is being held virtually on September 29-30, 2021.

    Dr. Bill Williams, BriaCell's President and CEO, will deliver his corporate presentation at 1:15pm ET on September 29.  Management will be available for one-on-one meetings to be held throughout the conference. Investors can register to receive a free spectator pass for the event: https://www.benzinga.com/events/small-cap/healthcare/.

    About BriaCell Therapeutics Corp.

    BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.

    Safe Harbor

    This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    Contact Information

    Company Contact:

    William V. Williams, MD

    President & CEO

    1-888-485-6340

    info@briacell.com

    Media Relations:

    Jules Abraham

    Director of Public Relations

    CORE IR

    917-885-7378

    julesa@coreir.com 

    Investor Relations Contact:

    CORE IR

    investors@briacell.com



    View Full Article Hide Full Article
  5. BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that its board of directors (the "Board") has authorized the Company's repurchase program whereby the Company may purchase through the facilities of the TSX Venture Exchange ("TSXV") or The NASDAQ Capital Market ("NASDAQ") (i) up to 1,341,515 common shares (the "Common Shares") and (ii) up to 411,962 publicly traded BCTXW warrants (the "Listed Warrants") in total, representing 10% of the 13,415,154 Common Shares and 10% of the 4,119,622 Listed Warrants…

    BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that its board of directors (the "Board") has authorized the Company's repurchase program whereby the Company may purchase through the facilities of the TSX Venture Exchange ("TSXV") or The NASDAQ Capital Market ("NASDAQ") (i) up to 1,341,515 common shares (the "Common Shares") and (ii) up to 411,962 publicly traded BCTXW warrants (the "Listed Warrants") in total, representing 10% of the 13,415,154 Common Shares and 10% of the 4,119,622 Listed Warrants comprising the "public float" as of September 8, 2021, over the next 12 months (the "Buyback"). Independent Trading Group (ITG) Inc. will act as the Company's advisor and dealer manager in respect of the Buyback. The Company expects to finalize the terms of the Buyback and formally commence the Buyback by September 14, 2021, subject to obtaining any necessary regulatory approvals.

    "BriaCell is in an excellent position and fully resourced to achieve significant milestones. Bria-IMT™ is steadily advancing toward a pivotal registration study that we plan to initiate in 2022. Also, Bria-OTS™ is on track to enter the clinic this year. Our novel immunotherapy cell lines for prostate cancer, lung cancer, and melanoma are all scheduled to enter the clinic in 2022. This robust pipeline will be a major value driver for BriaCell as we strive to deliver novel therapies for the patients who need them the most," stated Dr. Bill Williams, BriaCell's President & CEO. "In light of this enviable position, the Board has determined the best use of BriaCell's excess capital at this time is to buy back its own shares and warrants, and further enhance value for our shareholders."

    As of September 8, 2021, the Company had 15,269,583 Common Shares and 4,219,622 Listed Warrants issued and outstanding. BriaCell's cash balance as of July 31, 2021 was US$57 million. The repurchase program will in no way interfere with BriaCell's ambitious growth plans to expand into previously-announced areas of cancer immunotherapy and/or advance its current breast cancer clinical trials.

    BriaCell's proposed repurchases may be conducted through open market transactions at prevailing market prices, in privately negotiated transactions, in block trades, and/or through other legally permissible means, subject to the market conditions and in compliance with applicable rules and regulations. The timing and dollar amount of repurchase transactions will be subject to the Securities and Exchange Commission (the "SEC") Rule 10b-18 and/or Rule 10b5-1 requirements. Purchases of Common Shares or Listed Warrants through the NASDAQ will not, during the 12-month period, exceed 5% of the outstanding Common Shares or Listed Warrants in the aggregate, as at the commencement of the Buyback. Additionally, the program is subject to the approval by TSXV. BriaCell's Board of Directors will be reviewing the program periodically and may revise the terms and/or size or suspend or discontinue the program.

    About BriaCell Therapeutics Corp.

    BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.

    Safe Harbor

    This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    Contact Information

    Company Contact:

    William V. Williams, MD

    President & CEO

    1-888-485-6340

    info@briacell.com

    Media Relations:

    Jules Abraham

    Director of Public Relations

    CORE IR

    917-885-7378

    julesa@coreir.com 

    Investor Relations Contact:

    CORE IR

    investors@briacell.com



    Primary Logo

    View Full Article Hide Full Article
View All BriaCell Therapeutics Corp. News